Elaine Wong, MD
Endocrinology, Diabetes & Metabolism · Emeryville, CANPI 1932258258
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $47,431 of the $47,431 with a category attached, or 100.0%. Myovant Sciences Inc. accounts for 88.4% of it on its own, with 1 other manufacturer making up the rest. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 10 payments — averaging $4743.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myovant Sciences Inc.$42K
- Sumitomo Pharma America, Inc.$6K
What the payments were for
- Consulting fees$47,431100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Myovant Sciences Inc. | 7 | $41,913 |
| Sumitomo Pharma America, Inc. | 3 | $5,519 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORGOVYX$10,325
How this compares
$47,431 in reported general payments places this provider in the 90th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 123 | $244,360 |
| JardianceEmpagliflozin | 115 | $180,662 |
| MounjaroTirzepatide | 81 | $151,806 |
| SomavertPegvisomant | 12 | $143,264 |
| TrulicityDulaglutide | 60 | $79,808 |
| TymlosAbaloparatide | 24 | $72,708 |
| ForteoTeriparatide | 11 | $46,453 |
| FarxigaDapagliflozin Propanediol | 25 | $37,039 |
| Teriparatide | 11 | $27,089 |
| JanuviaSitagliptin Phosphate | 25 | $25,121 |
| Tresiba Flextouch U-100Insulin Degludec | 33 | $17,780 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 11 | $11,597 |
| SynthroidLevothyroxine Sodium | 72 | $7,761 |
| Testosterone | 49 | $7,478 |
| Humalog Kwikpen U-100Insulin Lispro | 28 | $6,618 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Emeryville
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.